SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-25-001914 to PMGC Holdings Inc. (ELAB)

PMGC Holdings Inc.
Date: Feb. 19, 2025 · CIK: 0001840563 · Accession: 0000000000-25-001914

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-284851

Date
February 19, 2025
Author
Graydon Bensler
Form
UPLOAD
Company
PMGC Holdings Inc.

Letter

February 19, 2025 Graydon Bensler Chief Executive Officer PMGC Holdings Inc. 120 Newport Center Drive, Ste. 250 Newport Beach, CA 92660 Re:PMGC Holdings Inc. Registration Statement on Form S-1 Filed February 12, 2025 File No. 333-284851 Dear Graydon Bensler: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Ross Carmel, Esq.

Show Raw Text
February 19, 2025
Graydon Bensler
Chief Executive Officer
PMGC Holdings Inc.
120 Newport Center Drive, Ste. 250
Newport Beach, CA 92660
Re:PMGC Holdings Inc.
Registration Statement on Form S-1
Filed February 12, 2025
File No. 333-284851
Dear Graydon Bensler:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Ross Carmel, Esq.